You are here: Industry Insights > Opioid Dependence

News List

Indivior Announces Launch of SUBOXONE Sublingual Film Generic americanpharmaceuticalreview
February 22, 2019
Indivior announced its U.S. affiliate, Indivior Inc., has launched an authorized generic version of SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. The authorized generic is being marketed and .....
Indivior launches generic version of Suboxone sublingual film pharmaceutical-technology
February 21, 2019
UK-based pharmaceutical company Indivior has launched a generic version of its Suboxone (buprenorphine and naloxone) sublingual film in the US for the treatment of opioid dependence....
Buvidal Weekly and Buvidal Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence firstwordpharma
November 29, 2018
Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal® Weekly and Buvidal® Monthly (CAM2038) for maintenance treatment of opioid dependence within a framework of medical, social
Buvidal Weekly and Buvidal Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence firstwordpharma
November 29, 2018
Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal® Weekly and Buvidal® Monthly (CAM2038) for maintenance treatment of opioid dependence within a framework of medical, social
Camurus Receives EU Approval for Weekly and Monthly Buvidal americanpharmaceuticalreview
November 29, 2018
Camurus announced the European Commission (EC) has approved weekly and monthly Buvidal (prolonged release buprenorphine) for the treatment of opioid dependence in adults and adolescents from 16 years of age. .....
Dr Reddy's just-approved opioid dependence generic blocked over US patent dispute pharmafile
June 22, 2018
Dr Reddy’s Laboratories has taken two steps forward an one step back after its generic version of Suboxone Film (buprenorphine/naloxone) secured FDA approval for the treatment of opioid dependence,
BioDelivery Sciences Announces Approval of Bunavail for Opioid Dependence americanpharmaceuticalreview
May 03, 2017
BioDelivery Sciences International announced the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Bunavail (buprenorphine and naloxone) buccal film (CIII)...